Most patients with CM should undergo dermatologic examination annually, and surgical excision is still the first choice for the majority of curative cases, while patients at a more advanced stage may be unresectable or already metastatic.13,14 In recent years, melanoma treatment has been revolutionized by applying targeted and/or immuno-therapies, including BRAF and MEK (MAP-ERK kinase) inhibitors, and immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte- associated antigen 4 antibodies and anti‐programmed cell death protein 1 antibodies).8 This evidence concerns the gene BRAF and melanoma.